阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效

目的探讨阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效。方法选取2018年6月至7月来我院眼科就诊的糖尿病黄斑水肿患者15例15眼,通过玻璃体内注射阿柏西普进行治疗。注射前和注射后1个月、2个月门诊复查时,分别检查患者最佳矫正视力(best corrected vision acuity,BCVA)和眼压,并行黄斑区光学相干断层成像,记录黄斑中心凹视网膜厚度(central foveal thickness,CFT)等。结果患者术前BCVA为0.31±0.12;阿柏西普玻璃体内注射术后1个月BCVA为0.44±0.12,和术前相比差异有统计学意义(P=0.009);术后2个月BCVA为0.53±0.13,和术前相比差异亦有统计学意义(P<0.001)。但术后两组数据之间差异无统计学意义(P=0.132)。黄斑区光学相干断层成像检查显示,术前CFT为(354.30±89.52)μm;阿柏西普玻璃体内注射术后1个月CFT为(233.10±49.54)μm,显著低于术前,差异有统计学意义(P<0.001);术后2个月CFT为(198.60±41.88)μm,显著低于术前,差异亦有统计学意义(P<0.001)。术后2个月CFT显著低于术后1个月,差异有统计学意义(P=0.038)。术后1个月、2个月间患者眼压以及与术前相比,差异均无统计学意义(均为P>0.05)。结论经玻璃体内注射阿柏西普可有效减轻糖尿病黄斑水肿病变程度,提高视力。

Intravitreal aflibercept injection for the treatment of diabetic macular edema

Objective　To observe the clinical effect of intravitreal injection of aflibercept for patients with diabetic macular edema （DME）.Methods　Totally，fifteen eyes of fifteen patients with DME who visited the Department of Ophthalmology，the First Affiliated Hospital of Soochow University，between June and July 2018 were included.Intravitreal aflibercept injection was conducted for treatment.The best corrected vision acuity （BCVA） and optical coherence tomography （OCT） were examined，and the central foveal thickness （CFT） and intraocular pressure were recorded before the injection，and 1 month，2 months after the injection at the follow-up time.Results　The BCVA in 1 month after injection was 0.44±0.12，which was significantly higher compared to that before injection （0.31±0.12） （P=0.009）.Also，the BCVA in 2 months after injection was 0.53±0.13，which was significantly higher compared to that before injection （P<0.001）.There was no significant difference in BCVA between 1 month and 2 months after injection （P=0.132）.The CFT examined by OCT in 1 month after injection was （233.10±49.54）μm，which was significantly decreased compared to that before injection［ （354.30±89.52）μm］（P<0.001）.Also，the CFT in 2 months after injection was （198.60±41.88）μm，which was significantly decreased compared to that before injection（P<0.001）.Besides，the CFT in 2 months after injection was significantly decreased compared to that in 1 month after injection （P=0.038）.There was no significant difference of intraocular pressure between 1 month and 2 months after injection and before injection （both P>0.05）.Conclusion　It is found that intravitreal injection of aflibercept can efficiently alleviate macular edema and promote BCVA for patients with DME.